English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, October 31, 2017
エーザイ: 中国で抗がん剤「レンバチニブ」の肝細胞がんに係る適応による新薬承認申請が受理
エーザイ、第10回アルツハイマー病臨床試験会議(CTAD)において、最新の知見を発表
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
Tuesday, October 24, 2017
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
Friday, October 13, 2017
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
エーザイ・富山化学・大正製薬、抗リウマチ剤「コルベット(R)錠 25mg」の日本における製造販売承認の承継と販売移管に合意
Wednesday, October 11, 2017
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Tuesday, October 10, 2017
エーザイ、中年期以降のもの忘れ改善薬「遠志(オンジ)の恵み(R)」新発売
Wednesday, October 4, 2017
エーザイ、Biotoscana社と中南米における独占的ライセンス契約を締結
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575